Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6991 to 7005 of 8896 results

  1. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

    This guidance has been updated and replaced by NICE healthtech guidance 690.

    Withdrawn guidance

  2. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34)

    This guidance has been updated and replaced by NICE diagnostics guidance 58.

    Withdrawn guidance

  3. Biomarker tests to help diagnose preterm labour in women with intact membranes (DG33)

    We have moved Diagnostics guidance 33 to become HealthTech guidance 476. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. Tests in secondary care to identify people at high risk of ovarian cancer (DG31)

    We have moved Diagnostics guidance 31 to become HealthTech guidance 453. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Adjunctive colposcopy technologies for assessing suspected cervical abnormalities: the DYSIS colposcope with DYSISmap and the ZedScan I (DG32)

    We have moved Diagnostics guidance 32 to become HealthTech guidance 467. This is to better reflect the NICE HealthTech programme, which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Lead-I ECG devices for detecting symptomatic atrial fibrillation using single time point testing in primary care (DG35)

    We have moved Diagnostics guidance 35 to become HealthTech guidance 508. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Point-of-care creatinine devices to assess kidney function before CT imaging with intravenous contrast (DG37)

    We have moved Diagnostics guidance 37 to become HealthTech guidance 530. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis (DG36)

    We have moved Diagnostics guidance 36 to become HealthTech guidance 521. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Rapid tests for group A streptococcal infections in people with a sore throat (DG38)

    We have moved Diagnostics guidance 38 to become HealthTech guidance 531. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Tests to help assess risk of acute kidney injury for people being considered for critical care admission (ARCHITECT and Alinity i Urine NGAL assays, BioPorto NGAL test and NephroCheck test) (DG39)

    We have moved Diagnostics guidance 39 to become HealthTech guidance 544. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    We have moved health technology evaluation 16 to become HealthTech guidance 712. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTE13)

    We have moved health technology evaluation 13 to become HealthTech guidance 697. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    We have moved health technology evaluation 14 to become HealthTech guidance 700. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)

    We have moved Health technology evaluation 17 to become HealthTech guidance 713. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTE18)

    We have moved Health technology evaluation 18 to become HealthTech guidance 718. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance